Pfizer Inc. announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP) has voted to expand its recommendation for PREVNAR 20, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine. The new recommendation includes all adults aged 50 and older.
This expanded recommendation, which is pending final approval by the CDC director and the Department of Health and Human Services, marks an important milestone in reducing the burden of pneumococcal disease. PREVNAR 20 offers protection against 20 serotypes responsible for a majority of invasive pneumococcal disease cases in this age group.
The decision provides an opportunity to limit the re-emergence of disease-causing strains, such as serotype 4, which has recently affected certain U.S. adult populations and is covered by the vaccine. This broader recommendation is expected to significantly increase the addressable market for PREVNAR 20.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.